Option chain shows key data for Nutroganics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nutroganics.

Nutroganics (OTC:NUTTQ) Stock, Option Chain

Nutroganics Inc focuses on acquiring and operating revenue-generating businesses in the healthy lifestyle space, primarily the nutritional supplement, and natural and organic food industries. These industries are highly susceptible to consumer demand, trends, and preferences. The company, through its subsidiary, produces, packages, and sells honey products. It sells its products to food manufacturers and national grocery chains under the Silverbow brand and private label brands. The group's business activity is principally conducted in the United States of America.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAWW

ABMD

ACRGF

ACTG

ADAP

AERO

AEZS

AGGZF

AKKVF

ALBO

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALKS

ALPN

ALXEF

ANDE

ANGI

ARHN

ARLP

Adtalem Global Education Inc. Common Stock

ATGE

AUPH

AWSM

AXAS

AXDDF

BCRX

BCTXF

BIEI

BLOZF

BLOK TECHNOLOGIES INC by Blok Technologies Inc.

BLPFF

BOIVF

BOSSY

BOTY

BRTX

BSTC

BTLLF

CEIX

CERS

CGNSF

CHKDG

CHKDP

CHOOF

CKISF

CLDPQ

CLVS

CMCT

CMRX

CMVLF

CNONF

CNSL

COTE

CRBP

CRZBY

CSLT

CTMX

CTST

CVEO

CWRK

CYIG

DFIN

DIIBF

DKAM

DNOW

DZSI

EBKDY

ECIFY

EMESQ

ENBL

EZPW

FANG

FELP

FENG

FLMN

FRHLF

FRLI

FRNKF

FSNNQ

FTCH

FTSI

FTSV

FULC

GAIA

GARB

GARLF

GDOT

Stocks That Hit 52-Week Lows On Tuesday

Nutroganics Inc

<p>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported quarterly losses of $(0.51) per share which met the analyst consensus estimate. This is a 65.31 percent increase over losses of $(1.47) per share from the same period last year.  The company reported quarterly sales of $88.31 million which beat the analyst consensus estimate of $84.38 million by 4.66 percent.  This is a 69.69 percent decrease over sales of $291.34 million the same period last year.</p>


Earnings

NVAX

Novavax Q4 2024 GAAP EPS $(0.51), Inline, Sales $88.31M Beat $84.38M Estimate

<p>Keefe, Bruyette &amp; Woods  analyst Timothy Switzer   upgrades Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) from Underperform to Market Perform and lowers the price target from $80 to $74.</p>


Upgrades

Price Target

Analyst Ratings

TFIN

Keefe, Bruyette & Woods Upgrades Triumph Financial to Market Perform, Lowers Price Target to $74

<p>Analysts' ratings for Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Bentley Systems, presenting an average target of $58.25, a high estimate of $62.00, and a low estimate of $52.00. This current average represents a 7.54% decrease from the previous average price target of $63.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740661300_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Bentley Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$52.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bentley Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bentley Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Bentley Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bentley Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BSY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Bentley Systems analyst ratings.</strong></a></p>
<h2>Get to Know Bentley Systems Better</h2>
<p>Bentley Systems is a software vendor that caters to engineers, architects, constructors, and geospatial professionals by enabling design, modeling, simulation, project management, and data management of infrastructure assets. The firm delivers solutions via the cloud, desktop, and hybrid environments. While Bentley is relatively small in comparison with peers like Autodesk, it shines in core specialty areas, like bridge or rail design, as opposed to being more broad-based in its applications. Bentley's largest end market is the public works and utilities sector, which represents approximately two thirds of revenue.</p>
<h3>Bentley Systems's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bentley Systems showcased positive performance, achieving a revenue growth rate of <strong>9.31%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>12.63%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Bentley Systems's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>4.2%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Bentley Systems's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.27%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.41</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 4 Analysts Discuss Bentley Systems Stock

<p>Needham  analyst Joseph Stringer   reiterates Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and maintains $19 price target.</p>


Reiteration

Needham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target

<p>During the last three months, 4 analysts shared their evaluations of Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.75, a high estimate of $63.00, and a low estimate of $33.00. This current average represents a 5.45% decrease from the previous average price target of $50.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740661283_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Tandem Diabetes Care. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tandem Diabetes Care. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Tandem Diabetes Care's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Tandem Diabetes Care analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Tandem Diabetes Care</h2>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Unraveling the Financial Story of Tandem Diabetes Care</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>31.43%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's net margin is impressive, surpassing industry averages. With a net margin of <strong>-9.53%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-9.86%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Tandem Diabetes Care's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.45%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.0</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TNDM

The Analyst Verdict: Tandem Diabetes Care In The Eyes Of 4 Experts

<p>10 analysts have expressed a variety of opinions on C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.4, along with a high estimate of $55.00 and a low estimate of $28.00. Witnessing a positive shift, the current average has risen by 24.67% from the previous average price target of $30.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740661261_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of C3.ai's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Underweight</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Kimson</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$32.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to C3.ai. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C3.ai compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of C3.ai's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of C3.ai's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on C3.ai analyst ratings.</strong></a></p>
<h2>Get to Know C3.ai Better</h2>
<p>C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.</p>
<h3>Key Indicators: C3.ai's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> C3.ai's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of <strong>28.83%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> C3.ai's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-69.93%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> C3.ai's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-7.61%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> C3.ai's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-6.27%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For C3.ai's Future

HUMA

Humacyte Issued US Patent Covering Manufacturing Of Symvess And Other Bioengineered Tissues

<p>Barrington Research  analyst Gary Prestopino   maintains CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) with a Outperform and maintains $14 price target.</p>


CCCS

Barrington Research Maintains Outperform on CCC Intelligent Solutions, Maintains $14 Price Target

<p>Comedian and former talk show host <strong>Ellen DeGeneres</strong> has a reputation for moving in and out of homes at a clip. However, she has surely broken her own record after moving to the UK in the wake of <strong>Donald Trump</strong>&#8216;s election win and purchasing an $18 million residence in the leafy <a href="https://www.benzinga.com/markets/24/12/42619049/celebrities-like-ellen-degeneres-david-beckham-and-simon-cowell-have-turned-englands-idyllic-cotswolds-into-a-list-mecca">Cotswolds</a>. However, <a href="https://www.dailymail.co.uk/news/article-14398619/Has-Ellen-fallen-love-15million-Cotswolds-dream-home-Residents-say-talk-queen-wife-Portia-Rossi-eyeing-new-rural-retreat-new-home-surrounded-floodwater.html">according to the Daily Mail</a>, DeGeneres is having second thoughts, having been flooded and running into problems with her neighbors.</p>
<p>It&#8217;s not that Ellen and her wife, <strong>Portia de Rossi</strong>, are reconsidering living in England. Rather, they are considering moving out of their historic, sprawling farmhouse in favor of a more modern home.&nbsp;</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast —<a href="https://www.benzinga.com/money/integris"><strong> </strong><strong>here&#8217;s how to invest in their private credit fund that targets 12% annual interest rate.</strong></a></strong></li>
<li><strong>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100"><strong>become a landlord in just 10 minutes, with minimum investments as low as $100</strong></a></strong><strong>.</strong></li>
</ul>
<p>&#8220;Ellen and Portia have had several issues with the place they initially moved into. First there was the flooding, of course, then there was an issue with some locals complaining about some building work carried out at the property,&#8221; a source told the Daily Mail.&nbsp;</p>
<p>The source added: &#8220;So the upshot seems to have been that they started to have a look around and then this property came up.They looked at it several times. And they liked it more each time they looked. So it does look like it&#8217;s happening. They&#8217;ve been seen around there several times in recent weeks and have even had interactions with neighbors.&#8221;</p>
<p><strong>Trending: Coinbase&#8217;s latest promo gets you up to $200 in crypto (Seriously!) — <a href="http://coinbase-consumer.sjv.io/m5ALXy"><strong>Here's everything you need to know to take advantage of this offer.</strong></a></strong></p>
<h2 class="wp-block-heading">From Old To Bold</h2>
<p>Their possible new home is the polar opposite of a classic rambling farmhouse. It&#8217;s strikingly modern, with clean lines, and it sits atop a hill, negating the chance of flooding.&nbsp;</p>
<p>It&#8217;s not as if Ellen has to worry about buying a newer home in the Cotswolds without selling the first property she purchased. She and de Rossi sold three homes in California in quick succession for staggering numbers before they left.&nbsp;</p>
<h2 class="wp-block-heading">Prolific House Flipper</h2>
<p>She sold two homes in <a href="https://www.benzinga.com/real-estate/25/01/43030678/meghan-markles-at-home-show-filmed-in-8-million-mansion-thats-not-hers">Montecito</a> last spring for<a href="https://people.com/home/ellen-degeneres-lists-modern-montecito-home-for-13-9-million-after-purchasing-it-in-september/"> $13.5 million</a> and<a href="https://people.com/ellen-degeneres-sells-stunning-montecito-mansion-after-renovation-8603096"> $32 million</a>, respectively, flipping them after buying them shortly before. Around the same time, she sold a Carpenteria cliffside estate for an alarming $96 million, earning a sizable $26 million profit, according to<a href="https://www.realtor.com/news/celebrity-real-estate/ellen-degeneres-los-angeles-mansion-sold-profit/"> Realtor.com</a>. Indeed, before leaving the U.S., DeGeneres was a prolific flipper, buying and selling over<a href="https://www.marketwatch.com/story/ellen-degeneres-makes-a-big-return-in-netflix-special-but-her-real-estate-empire-might-be-the-real-winner-2c16f04f"> 50 luxury homes</a>, often selling them to<a href="https://www.realtor.com/news/celebrity-real-estate/ellen-degeneres-netflix-real-estate-lucrative/"> celebrity friends</a>.&nbsp;</p>
<p>&#8220;I don&#8217;t really travel a lot. So, house flipping is my version of travel,&#8221; she told<a href="https://issuu.com/santabarbarasentinel/docs/_riv_16_1_full"> Riv Magazine</a> in 2023. &#8220;With house flipping, the scenery changes, though I stay in the same general area. Only in a new place and from a new perspective.&#8221;</p>
<p><strong><em>See Also: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares-y2"><strong><em> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">$450 Million Net Worth</h2>
<p>According to<a href="https://www.forbes.com/profile/ellen-degeneres/"> Forbes</a>, Ellen was worth $450 million last year. She made her money principally from TV—her talk show ran for 19 seasons — and house flipping.</p>
<p>In 2020,<a href="https://variety.com/2020/tv/news/ellen-crew-furious-over-poor-communication-regarding-pay-non-union-workers-during-coronavirus-shutdown-exclusive-1234582735/"> Variety</a> reported that Ellen made as much as $50 million per year from her deal with Telepictures, the production company that produced &#8220;The Ellen DeGeneres Show.&#8221;&nbsp;&nbsp;</p>
<p>In addition to her own show, the stand-up comedian was also an<a href="https://www.imdb.com/name/nm0001122/"> executive producer</a> on multiple shows, including &#8220;Bethenny,&#8221; &#8220;Repeat After Me,&#8221; &#8220;Little Big Shots,&#8221; &#8220;Green Eggs and Ham&#8221; and &#8220;Little Ellen.&#8221; She was also an actress and earned<a href="https://www.forbes.com/sites/maddieberg/2018/07/18/how-ellen-made-history-and-87-million-this-year/"> $20 million</a> for a 2018 <a href="https://www.benzinga.com/insights/news/25/02/43851978/heres-how-much-100-invested-in-netflix-20-years-ago-would-be-worth-today">Netflix</a> special.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a></strong>,<strong> which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf"><strong> </strong></a></strong></li>
<li><strong>Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"><strong> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</strong></a></strong></li>
</ul>


Real Estate

Ellen DeGeneres and Portia de Rossi's Quest For A UK Home Continues After Their $18 Million Farmhouse Purchase Runs into Problems.

<p>During the last three months, 6 analysts shared their evaluations of Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Agilent Technologies and provided 12-month price targets. The average target is $151.67, accompanied by a high estimate of $159.00 and a low estimate of $145.00. Marking an increase of 2.13%, the current average surpasses the previous average price target of $148.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740661239_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Agilent Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$159.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$156.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agilent Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agilent Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Agilent Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Agilent Technologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/A/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Agilent Technologies analyst ratings.</strong></a></p>
<h2>Discovering Agilent Technologies: A Closer Look</h2>
<p>Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.</p>
<h3>Agilent Technologies's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of <strong>0.77%</strong> as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Agilent Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>20.63%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Agilent Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.95%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Agilent Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.07%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.57</strong>, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Agilent Technologies Through 6 Analysts

<p>In the latest quarter, 7 analysts provided ratings for Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Synaptics, revealing an average target of $98.14, a high estimate of $105.00, and a low estimate of $90.00. This upward trend is evident, with the current average reflecting a 5.04% increase from the previous average price target of $93.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740661222_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Synaptics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Synaptics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Synaptics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Synaptics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Synaptics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SYNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Synaptics analyst ratings.</strong></a></p>
<h2>Delving into Synaptics's Background</h2>
<p>Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.</p>
<h3>Unraveling the Financial Story of Synaptics</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Synaptics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>12.74%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Synaptics's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.67%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Synaptics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.13%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Synaptics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.07%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.64</strong>, Synaptics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SYNA

Expert Outlook: Synaptics Through The Eyes Of 7 Analysts

<p>Needham  analyst David Saxon   reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Hold to Hold.</p>


STAA

Needham Reiterates Hold on Staar Surgicalto Hold

<p>Goldman Sachs  analyst Julien Blouin   initiates coverage on Millrose Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) with a Buy rating and announces Price Target of $25.</p>


Initiation

Goldman Sachs Initiates Coverage On Millrose Properties with Buy Rating, Announces Price Target of $25

<p>Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.32 by 18.75 percent. This is a 46.15 percent increase over earnings of $0.26 per share from the same period last year.  The company reported quarterly sales of $75.38 million which missed the analyst consensus estimate of $76.47 million by 1.43 percent.  This is a 15.97 percent increase over sales of $65.00 million the same period last year.</p>


Earnings Beats

Earnings Misses

VCEL

Vericel Q4 EPS $0.38 Beats $0.32 Estimate, Sales $75.38M Miss $76.47M Estimate

<p>Needham  analyst Mike Cikos   reiterates C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Hold to Hold.</p>


Needham Reiterates Hold on C3.aito Hold

<p>Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is looking for FY2025 Adj EPS of $4.75 vs $4.48 analyst estimate. sees sales of $2.170 billion vs $2.15 billion analyst estimate.</p>


Guidance

Koppers Hldgs Sees FY2025 Adj EPS $4.75 vs $4.48 Est; Sees Sales $2.170B vs $2.15B Est

<p>Goldman Sachs  analyst Bonnie Herzog   maintains Vita Coco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCO#NASDAQ">COCO</a>) with a Buy and raises the price target from $34 to $38.</p>


COCO

Goldman Sachs Maintains Buy on Vita Coco, Raises Price Target to $38

<p>Barrington Research  analyst Gary Prestopino   maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.</p>


Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

<p>Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) reported quarterly earnings of $0.77 per share which missed the analyst consensus estimate of $0.92 by 16.3 percent. This is a 14.93 percent increase over earnings of $0.67 per share from the same period last year.  The company reported quarterly sales of $477.00 million which missed the analyst consensus estimate of $500.83 million by 4.76 percent.  This is a 7.05 percent decrease over sales of $513.20 million the same period last year.</p>


Koppers Hldgs Q4 Adj EPS $0.77 Misses $0.92 Estimate, Sales $477.00M Miss $500.83M Estimate

<p>B of A Securities  analyst Wamsi Mohan   maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Neutral and lowers the price target from $77 to $73.</p>


PSTG

B of A Securities Maintains Neutral on Pure Storage, Lowers Price Target to $73

Nutroganics

Comments

Nutroganics

Nutroganics (NUTTQ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga